Results 151 to 160 of about 412,948 (294)

Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation

open access: yesAdvanced Science, EarlyView.
This review redefines radiotherapy‐triggered drug delivery systems through structural disassembly and molecular actuation, proposing a translation‐oriented framework for dose‐correlated activation to advance clinically integrated precision oncology. ABSTRACT Radiotherapy‐triggered drug delivery systems (RDDS) promise to integrate the spatial precision ...
Jianv Jiang   +3 more
wiley   +1 more source

Mutation Spectrum of Hemoglobinopathies in Tunisia. [PDF]

open access: yesHum Mutat
Moumni I   +10 more
europepmc   +1 more source

Carrier‐Free Stimulus‐Responsive Theranostic Nanoprodrug Enabling GSH‐Consumption‐Promoted Chemo‐Photodynamic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Leveraging the critical role of glutathione (GSH) in mediating drug resistance and scavenging reactive oxygen species (ROS) in cancer cells, a carrier‐free GSH‐consuming theranostic nanoprodrug, consisting of a BODIPY photosensitizer and the chemotherapeutic drug paclitaxel linked through a GSH‐consuming drug linker, is developed to deeply explore the ...
Hansheng Huang, Binglin Sui
wiley   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

open access: yesAdvanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu   +6 more
wiley   +1 more source

Evolution of hemoglobinopathy diagnosis over 30 years in southern Spain: impact of migration and laboratory screening strategies. [PDF]

open access: yesLab Med
Molina-Arrebola MA   +5 more
europepmc   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy